Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study.

ABSTRACT:

Background

Precision oncology using genotype-matched treatments (GMT) offers potential to improve survival in metastatic castration-resistant prostate cancer (mCRPC).

Patient and methods

In the PROMPT study (NCT04746300), reflex tumour testing through next-generation sequencing was performed in treatment-naïve or first-line mCRPC patients. All patients received a molecular tumour board (MTB) recommendation for GMT based on predefined druggable targets (DT). The main objective was to identify clinicopathological variables associated with DT.

Results

Analysis included 340 tissue samples from 307 patients, 51% of samples were newly biopsied. Valid results were generated in 84% (76% new, 92% archived; P < 0.01). DT were identified in 39% of the patients, with PI3K-AKT (26

SUBMITTER: Kloots ISH 

PROVIDER: S-EPMC12820098 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature